TEA-ACLF
Liver Transplantation for EASL-CLIF and APASL ACLF Patients: a Retrospective Cohort Study to Evaluate Different Criterion in Predicting Post-transplant Outcomes
Sponsor study identifier
observational
500
0 countries
N/A
Study Start
September 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
October 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
October 31, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The definition and diagnostic criteria of acute-on chronic liver failure (ACLF) differed evidently between the East and the West due to the difference in the underlying etiology. Liver transplantation is the most effective treatment to reverse the progress of ACLF and improve the survival rate of patients. The purpose of this study is to explore the accuracy of the two diagnostic criteria of EASL-CLIF and APASL ACLF in assessing the survival rate of patients with liver cirrhosis after LT.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 31, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 1, 2021
Actual (reported)September 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
September 5, 2021
Actual (reported)October 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
October 31, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
3 years overall survival
Up to ~3 years
patients underwent liver transplantation for cirrhosis at Renji Hospital, School of Medicine, Shanghai Jiao Tong University, China between January 2015 and June 2020 were considered for inclusion.
Qiang Xia
Dept. Liver Surgery, Renji Hospital, School of Medicine, SJTU
Hao Feng
Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
First Submitted
September 1, 2021
First Posted
September 5, 2021
Study Start
September 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
October 1, 2021
Estimated (date passed)SALT for Treatment of Patients With Early ACLF
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
October 31, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
September 5, 2021
Record last verified: 2021-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: